CureLab Oncology obtains a US patent for the therapeutic use of its flagship product in the diseases of ALS, Alzheimer’s, Huntington’s and Parkinson’s
BOSTON, July 20, 2021 / PRNewswire / – CureLab Oncology, a clinical-stage biotechnology company, has obtained a US patent for the application of its flagship product for the treatment of ALS, Alzheimer’s disease, Huntington, and Parkinson’s disease. These patent applications have already been granted in Asia and Europe.
Today, 5 million Americans suffer from Alzheimer’s, 1 million from Parkinson’s, 30,000 from Huntington disease and 30,000 from ALS. The incidence of these diseases is expected to increase as the population ages.
“Our current product is circular DNA encoding a particular protein, p62. However, it can be modified into a wide variety of alternative forms, including a therapeutic microbiome. In fact, we recently published an article demonstrating that Lactobacillus lactis containing circular DNA with an inserted p62 gene reduces the signs of Alzheimer’s disease in mice. All of these alternative products are covered by the granted patent, “said Dr. Franco Venanzi, director of basic research at CureLab.
CureLab’s research focuses on a new treatment strategy for these diseases since neurodegenerative diseases, such as some cancers, involve chronic inflammation in their pathogenesis. CureLab’s flagship product, Elenagen ™, reduces chronic inflammation. In its ongoing cancer clinical studies, CureLab observed a desirable safety profile and preliminary evidence of the clinical benefit of Elenagen for cancer patients.
“With this patent, we continue to extend, strengthen and protect our world-wide patents of p62-based gene therapy,” said Alexandre shneider, Ph.D., CEO of CureLab Oncology. “Other applications of our product have become evident from mechanical knowledge of its anti-cancer effect. This anti-neurodegenerative dimension of our work does not distract us from our clinical cancer trials, but rather adds a synergistic component to our R&D. “
CureLab is planning clinical trials to establish the efficacy of its flagship product and its variants for the treatment of neurodegenerative diseases.
For more information see “Neuroprotective effects of p62-modified lactic acid bacteria (SQSTM1) in Alzheimer’s disease: a preclinical study” in Aging, August 29. 2020.
About CureLab Oncology
CureLab Oncology Inc. is a pre-IPO clinical stage immuno-oncology biotechnology company, headquartered in the largest Boston area. CureLab is dedicated to advancing new safer therapies for solid tumors and other oncological and inflammatory indications. To learn more, visit curelab.com.
Tim cox, ZingPR, [email protected]
SOURCE CureLab Oncology Inc.